Comparison
CJC-1295 vs. GHRP-6
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Growth
CAS no.
no data
87616-84-0
Molecular weight
3647.3 g/mol
873.02 g/mol
Half-life
144 h
0.4 h
Sequence
YADAIFTNSYRKVLGQLSARKLLQDIMSR-DACHis-D-Trp-Ala-Trp-D-Phe-Lys-NH2Mechanism of action
CJC-1295
Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.
GHRP-6
GHRP-6 is a high-affinity agonist of the growth-hormone secretagogue receptor 1a (GHSR-1a) — the same receptor later shown to bind the endogenous hormone ghrelin. The identification of GHRP-6 as a pharmacological anchor led to cloning of GHSR in 1996 and the discovery of ghrelin itself in 1999. GHRP-6 stimulates pituitary GH secretion via a pathway independent of GHRH and can be combined synergistically with GHRH. Via GHSR in the hypothalamus it additionally activates NPY/AgRP neurons, producing an orexigenic (appetite-stimulating) effect in animal models.
Evidence base
Highest evidence
Human trial
Human trial
Studies
3
4
of which in humans
2
2
Effects recorded
3
4
Open conflicts
1
1
Documented adverse events
3
2